Literature DB >> 35157098

[Molecular diagnostics and molecular tumor board in uro-oncology : Precision medicine using the example of metastatic castration-resistant prostate cancer].

Kira Kornienko1,2, Rana Tahbaz3, Henning Plage3, Thorsten Schlomm4.   

Abstract

Novel approaches to molecular tumor profiling evaluate DNA, RNA and protein alterations to create a detailed molecular map that enables precise and personalized treatment decisions. As the field of molecular profiling is constantly evolving, the training and networking of doctors is of decisive importance. Through the establishment of precision medicine with precision oncological consultations supported by interdisciplinary molecular tumor boards, many patients with difficult to treat tumor diseases can be advised and treated. Many pathophysiological relationships in progressive tumors can be elucidated resulting in new therapeutic options for the profiled patients; however, understanding the complex mutational profiles remains a very demanding task that requires a suitably trained and committed team that should be in close contact with the scientific advancements in precision oncology.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Interdisciplinary tumor board; Mutation; Next generation sequencing; Poly(ADP-ribose) polymerase inhibitors; Precision oncology

Mesh:

Year:  2022        PMID: 35157098     DOI: 10.1007/s00120-022-01784-w

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  29 in total

Review 1.  The genetic basis for cancer treatment decisions.

Authors:  Janet E Dancey; Philippe L Bedard; Nicole Onetto; Thomas J Hudson
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

Review 2.  The current state of molecular testing in the treatment of patients with solid tumors, 2019.

Authors:  Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall
Journal:  CA Cancer J Clin       Date:  2019-05-22       Impact factor: 508.702

3.  Sensitive tumour detection and classification using plasma cell-free DNA methylomes.

Authors:  Shu Yi Shen; Rajat Singhania; Gordon Fehringer; Ankur Chakravarthy; Michael H A Roehrl; Dianne Chadwick; Philip C Zuzarte; Ayelet Borgida; Ting Ting Wang; Tiantian Li; Olena Kis; Zhen Zhao; Anna Spreafico; Tiago da Silva Medina; Yadon Wang; David Roulois; Ilias Ettayebi; Zhuo Chen; Signy Chow; Tracy Murphy; Andrea Arruda; Grainne M O'Kane; Jessica Liu; Mark Mansour; John D McPherson; Catherine O'Brien; Natasha Leighl; Philippe L Bedard; Neil Fleshner; Geoffrey Liu; Mark D Minden; Steven Gallinger; Anna Goldenberg; Trevor J Pugh; Michael M Hoffman; Scott V Bratman; Rayjean J Hung; Daniel D De Carvalho
Journal:  Nature       Date:  2018-11-14       Impact factor: 49.962

4.  Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.

Authors:  Nicola Normanno; Anna Maria Rachiglio; Cristin Roma; Francesca Fenizia; Claudia Esposito; Raffaella Pasquale; Maria Libera La Porta; Alessia Iannaccone; Filippo Micheli; Michele Santangelo; Francesca Bergantino; Susan Costantini; Antonella De Luca
Journal:  J Cell Biochem       Date:  2013-03       Impact factor: 4.429

Review 5.  Towards precision oncology in advanced prostate cancer.

Authors:  Sheng-Yu Ku; Martin E Gleave; Himisha Beltran
Journal:  Nat Rev Urol       Date:  2019-10-07       Impact factor: 14.432

6.  Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study.

Authors:  Valentina Gambardella; Pasquale Lombardi; Juan Antonio Carbonell-Asins; Noelia Tarazona; Juan Miguel Cejalvo; Inés González-Barrallo; Jorge Martín-Arana; Roberto Tébar-Martínez; Alba Viala; Gema Bruixola; Cristina Hernando; Inma Blasco; Federica Papaccio; Carolina Martínez-Ciarpaglini; Clara Alfaro-Cervelló; Enrique Seda-García; Sebastián Blesa; Isabel Chirivella; Josefa Castillo; José Vicente Montón-Bueno; Susana Roselló; Marisol Huerta; Alejandro Pérez-Fidalgo; Paloma Martín-Martorell; Amelia Insa-Mollá; Tania Fleitas; Pilar Rentero-Garrido; Sheila Zúñiga-Trejos; Andrés Cervantes; Desamparados Roda
Journal:  Br J Cancer       Date:  2021-09-07       Impact factor: 9.075

7.  Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

Authors:  Gopa Iyer; Hikmat Al-Ahmadie; Nikolaus Schultz; Aphrothiti J Hanrahan; Irina Ostrovnaya; Arjun V Balar; Philip H Kim; Oscar Lin; Nils Weinhold; Chris Sander; Emily C Zabor; Manickam Janakiraman; Ilana R Garcia-Grossman; Adriana Heguy; Agnes Viale; Bernard H Bochner; Victor E Reuter; Dean F Bajorin; Matthew I Milowsky; Barry S Taylor; David B Solit
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

Review 8.  Molecular profiling for precision cancer therapies.

Authors:  Eoghan R Malone; Marc Oliva; Peter J B Sabatini; Tracy L Stockley; Lillian L Siu
Journal:  Genome Med       Date:  2020-01-14       Impact factor: 11.117

9.  Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA.

Authors:  Justin D Finkle; Hala Boulos; Terri M Driessen; Christine Lo; Richard A Blidner; Ashraf Hafez; Aly A Khan; Ariane Lozac'hmeur; Kelly E McKinnon; Jason Perera; Wei Zhu; Afshin Dowlati; Kevin P White; Robert Tell; Nike Beaubier
Journal:  NPJ Precis Oncol       Date:  2021-07-02

Review 10.  Artificial intelligence for precision medicine in neurodevelopmental disorders.

Authors:  Mohammed Uddin; Yujiang Wang; Marc Woodbury-Smith
Journal:  NPJ Digit Med       Date:  2019-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.